The tumor genetics of acral melanoma: What should a dermatologist know?Capsule Summary

• Main Authors: Bianca M. Tod, MMed (Derm), FCDerm, Johann W. Schneider, FCPath (SA) Anat, MMed (Anat Path), Anne M. Bowcock, PhD, Willem I. Visser, MMed (Derm), MFamMed, Maritha J. Kotze, PhD
• Format: Article
• Language: English
• Published: Elsevier 2020-12-01
• Series: JAAD International
• Subjects: acral melanoma; dermatology; genetics; melanoma; molecular; oncology
• Online Access: http://www.sciencedirect.com/science/article/pii/S2666328720300341

Dermatologists stand at the gateway of individualization of classification, treatment, and outcomes of acral melanoma patients. The acral melanoma genetic landscape differs in vital ways from that of other cutaneous melanomas. These differences have important implications in understanding pathogenesis, treatment, and prognosis. The selection of molecularly targeted therapy must be adapted for acral melanoma. It is also critical to recognize that tumor development is far more complex than an isolated event, reliably treated by a medication acting on a single target. Tumors exhibit intratumor genetic heterogeneity, metastasis may have different genetic or epigenetic features than primary tumors, and tumor resistance may develop because of the activation of alternative genetic pathways. Microenvironmental, immune, and epigenetic events contribute and sustain tumors in complex ways. Treatment strategies with multiple targets are required to effectively disrupt the tumor ecosystem. This review attempts to translate the current molecular understanding of acral melanoma into digestible concepts relevant to the practice of dermatology. The focus is tumor genetics defining potentially treatable cancer pathways, contextualized within the relevant pathologic and molecular features.